YOLFTbeta
Yarrow Bioscience Inc

Yarrow Bioscience Inc

YARW · NASDAQ · Healthcare / Biotechnology

18.03USD-1.60 (-8.15%)

Price History

Full chart

Market Stats

Previous Close19.63
Open19.33
Day Range17.99 – 19.86
52-Week Range8.95 – 44.28
Volume99.11K
Market Cap204.14M
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield73.09%
Beta2.07
50-Day Avg34.04
200-Day Avg31.57

About

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Rebecca Velez Frey Pharm.D.
  • Employees7
  • Headquarters40 10 th Avenue, New York, NY, United States, 10014, USA
  • Websitehttps://www.yarrowbioscience.com

Leadership

  • Ms. Rebecca Velez Frey Pharm.D.President, CEO & Director
  • Mr. Tyler Zeronda CPAChief Financial Officer · b. 1986
  • Ms. Rachael Alford Ph.D.Chief Operating Officer
  • Dr. Lori Payton Ph.D.Chief Development Officer
  • Dr. Steven W. Ryder F.A.C.P, M.D.Chief Medical Officer · b. 1951

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-674.00K4.58M10.64M443.00K20.99M931.00K477.00K424.00K501.00K570.00K
Growth (%)--+579.82%+132.21%-95.84%+4638.83%-95.57%-48.76%-11.11%+18.16%+13.77%
Cost of Revenue----350.00K1.39M----23.00K
Gross Profit-674.00K4.58M10.64M93.00K19.60M931.00K477.00K424.00K501.00K547.00K
Gross Margin-100.00%100.00%100.00%20.99%93.37%100.00%100.00%100.00%100.00%95.96%
Operating Expense-15.01M34.17M65.17M76.33M-232.94M39.84M34.77M29.68M44.14M30.30M
Operating Income-4.61M-14.33M-29.59M-54.53M-76.24M252.55M-38.91M-34.30M-29.26M-43.64M-29.75M
Operating Margin--2126.41%-645.85%-512.55%-17210.38%1203.00%-4179.48%-7189.73%-6900.47%-8709.98%-5219.12%
EBITDA-4.61M-14.33M-29.59M-54.53M-94.08M-251.09M-38.04M-33.86M-27.87M-39.80M-26.73M
EBITDA Margin--2125.82%-645.85%-512.55%-21237.70%-1196.09%-4086.04%-7098.53%-6573.58%-7943.91%-4689.82%
Net Income-4.61M-14.07M-29.08M-51.45M-70.46M-255.57M-73.33M-23.21M-28.45M-39.83M-26.48M
Net Income Margin--2087.24%-634.57%-483.51%-15906.09%-1217.40%-7876.37%-4865.83%-6710.38%-7950.90%-4646.14%
R&D2.92M11.26M29.01M52.99M53.76M43.53M19.54M18.39M16.31M30.95M19.24M
R&D as % of Total Revenue-1669.88%633.06%498.02%12135.67%207.37%2099.14%3854.30%3845.99%6176.85%3374.91%
Interest Expense----921.00K4.39M5.61M----
Interest Expense % of Total Revenue----207.90%20.91%602.58%----

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets43.88M42.05M66.87M139.93M79.17M93.74M67.05M40.76M97.69M66.91M30.16M
Total Liabilities59.84M71.49M123.90M9.55M10.66M56.25M18.41M9.56M8.95M14.82M2.40M
Total Equity-15.95M-29.44M-57.03M130.38M68.51M37.49M48.64M31.20M88.73M52.09M27.77M
Cash43.81M4.03M10.21M49.51M30.78M57.56M42.25M30.91M30.62M19.93M24.03M
Total Debt----700.00K34.78M349.00K-214.00K99.00K-
Net Debt-43.81M-4.03M-10.21M-49.51M-30.08M-22.78M-41.90M-30.91M-30.41M-19.83M-24.03M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.18M-2.29M-28.25M-52.73M-65.10M-137.08M-56.37M-29.20M-25.34M-33.97M-33.12M
Investing Cash Flow--37.49M-15.06M-33.88M41.37M89.11M1.03M15.67M-57.35M23.36M37.37M
Financing Cash Flow47.72M-49.49M125.91M4.99M61.81M39.78M1.65M82.39M-141.00K-143.00K
Capital Expenditure031.00K27.00K140.00K11.00K113.00K000117.00K0
Free Cash Flow-4.18M-2.32M-28.27M-52.87M-65.11M-137.19M-56.37M-29.20M-25.34M-34.09M-33.12M
FCF to OCF100.00%101.35%100.10%100.27%100.02%100.08%100.00%100.00%100.00%100.34%100.00%

Earnings

Report DateMar 29, 2018May 10, 2018Aug 2, 2018Nov 8, 2018Feb 28, 2019May 3, 2019Aug 2, 2019Nov 1, 2019Mar 4, 2020May 11, 2020Aug 6, 2020Nov 5, 2020Mar 4, 2021May 6, 2021Aug 12, 2021Nov 10, 2021Mar 17, 2022May 13, 2022Aug 12, 2022Nov 11, 2022Mar 10, 2023May 12, 2023Aug 14, 2023Nov 13, 2023Feb 29, 2024May 9, 2024Aug 14, 2024Nov 7, 2024Mar 6, 2025May 8, 2025Aug 14, 2025Nov 6, 2025May 7, 2026Aug 13, 2026Nov 5, 2026
EPS Estimate-----------------------------------
EPS Actual-1453.44-2591.38-1313.79-2012.78-2734.06-2917.72-2482.56-2532.98-3217.88-3407.17-4347.43-530.42-494.01-378.47-348.79-368.20-194.5475.89-131.68-146.95-166.58-86.36-153.60-100.30-9.96-7.34-11.04-14.27-14.11-10.09-6.73-8.50-4.19-2.14-
Surprise-----------------------------------
Timing-----------------------------------

Key Statistics & Ratios

Market Cap204.14M
Enterprise Value212.35M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.00
Book Value-26.06
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding8.44M
Shares Float1.75M
Beta2.07
Dividend Yield73.09%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
26.02%
Insiders
2.02%
Retail / Other
71.96%

Top Fund Holders

  • Fidelity Extended Market Index
    2.84K0.11%
  • Fidelity Series Total Market Index
    6940.03%
  • Fidelity Total Market Index
    4270.02%
  • Fidelity Nasdaq Composite Index
    70.00%

Dividends

20262×
20.10Jul 24, 20260.40Jul 22, 2026

Stock Splits

  • Jul 27, 20261:50
  • Feb 13, 20231:18
  • Feb 16, 20211:4